UPDATED ALEX TRIAL RESULTS: ALECTINIB▼ – NEW STANDART IN TREATMENT ALK POSITIVE NONSMALL CELL LUNG CANCER

Abstract

Targeted therapy is a relatively new way of treating lung cancer. First line treatment of adult patients with anaplastic lymphoma kinase (ALK) gene translocation positive non-small cell lung cancer is ALK tyrosine kinase inhibitors. In phase III ALEX study was compared the efficacy and safety of alectinib versus crizotinib in treatment people with previously untreatedmetastatic ALK positive non small cells lung cancer. Follow-up results from the ALEX study demonstrate the significant sustained benefit of alectinib, showing that peoplewithmetastatic ALK positive non-small cell lung cancer lived for almost three
years without their disease progressing. These results further support the use of ALK tyrosine kinase inhibitors like Alectinib as a standard of care for people who are newly diagnosed with this form of lung cancer.